Urological Cancer 2022
López, José I. (editor)
Manini, Claudia (editor)
In the urological sphere, the number of tumor malignancies caused by cancer is continuously growing in Western countries. Although this is mainly due to the contemporary increase in the life expectancy of people in these geographic areas, many other factors are also contributing to this growth. Urological cancer is a complex and varied disease which affects different organs and mainly affects the male population. In fact, in most statistics, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males. The female population, however, has also been increasingly affected by renal and bladder cancer in the last decade. From these facts, it is clear that urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light on the complexity of this field and will consider all useful and appropriate contributions from scientists and clinicians in order to improve urological cancer knowledge for patients’ benefit.
Keywordshigh-risk prostate cancer; androgen receptor axis; castration resistance; neuroendocrine carcinoma; PARP inhibition; immunotherapy; cancer genome; precision targeting; robot-assisted partial nephrectomy; renal cell carcinoma; indocyanine green; nephron sparing; prostate cancer survivors; follow-up care; primary health care; general practice; process evaluation; Consolidated Framework for Implementation Research; prostate-specific membrane antigen positron-emission tomography; multiparametric magnetic-resonance imaging; primary diagnosis; prostate cancer; systematic review; diagnosis; PSMA; PSA; tumor; PET scan; bladder cancer; bisphenol A; bisphenol S; energy metabolism; migration; proliferation; carbon-ion radiotherapy; elderly patients; radiotherapy; particle beam therapy; life expectancy; systemic immune-inflammation index; Charlson comorbidity index; CAPRA-S; early survival; male incontinence; robotic prostatectomy; clear cell renal cell carcinoma; ferroptosis; prognostic model; TCGA; E-MTAB-1980; GLS2; pazopanib; real-world data; non-interventional study; time on drug; nivolumab; everolimus; trial-eligibility; ureteral neoplasms; urinary bladder neoplasms; ureteroscopy; CNTF; CNTFRα; LNCaP; 22Rv1; castration resistant; castration sensitive; STAT3; ERK; MMP; biomarker; Gleason grade; transforming growth factor-β family; activin; INHBA; INHBB; INHBC; prostate-specific antigen; false-positive results; real world-data; n/a
Webshop linkhttps://mdpi.com/books/pdfview ...
Publication date and placeBasel, 2023